Skip to content
Chemotherapy · Immunotherapy · Targeted Therapy · Second Opinion

Medical Oncology in Turkey — Second Opinion, Tumor Board, and Systemic Treatment at Eyeglow Istanbul

Multi-disciplinary tumor board review, second opinion for solid tumors and hematological cancers, and systemic treatment administration — chemotherapy, immunotherapy (checkpoint inhibitors), targeted therapy, and hormone therapy — coordinated through Eyeglow Health's accredited partner oncology network at JCI-aligned hospitals in Istanbul. ESMO, NCCN, and ASCO guideline-aligned. Molecular profiling (NGS) available. Honest disclosure: treatment intent (curative versus disease-control) is stated explicitly in every written care plan.

Request oncology second opinion Browse other treatments
Medical oncology at Eyeglow, Istanbul
Second opinion turnaround3–5 working days
Tumor board reviewMulti-disciplinary, NCCN standard
Molecular profiling (NGS)Available on request
Partner hospital accreditationJCI-aligned, Turkish MoH certified
Guideline alignmentESMO · NCCN · ASCO

Verified and listed across leading directories and authorities

Verified across global platforms.
Real patient reviews, openly listed worldwide.
What it is

What is medical oncology?

Medical oncology is the medical specialty responsible for diagnosis staging confirmation and non-surgical treatment of cancer — chemotherapy, immunotherapy, targeted therapy, and hormone therapy. The medical oncologist works alongside surgical oncologists and radiation oncologists in a multi-disciplinary tumor board (MDT) to determine the most appropriate treatment for each patient. At Eyeglow Health, medical oncology is coordinated through our accredited partner network of board-certified medical oncologists at JCI-aligned hospitals in Istanbul, following ESMO, NCCN, and ASCO practice guidelines.

A second opinion — independent review of your pathology, staging, and proposed treatment plan — changes the recommended management in 10–30% of cases in published oncology literature. We offer full second-opinion coordination including tumor board presentation and a written comparison of your current plan versus the board recommendation, returned within 3–5 working days of complete document receipt.

How it works

From second opinion to treatment completion

  1. 01

    Initial consultation + document review

    You share your pathology reports (biopsy, histology, receptor status — ER/PR/HER2 for breast, microsatellite instability status for colorectal, EGFR/ALK/ROS1 for lung), imaging (CT, PET-CT, MRI, bone scan), prior treatment history (chemotherapy regimens received, doses, response, toxicity), current medications, performance status (ECOG), and comorbidities. Our oncology coordinator reviews completeness of staging workup and flags any gaps. The partner oncologist receives a full pre-clinic summary before your consultation.

  2. 02

    Oncologist assessment + staging confirmation

    The partner board-certified medical oncologist reviews your case in detail: confirms TNM staging and AJCC classification, assesses histological subtype and molecular markers (receptor status, mutation profile, microsatellite instability, TMB where relevant), and identifies whether your current or proposed treatment plan aligns with ESMO, NCCN, or ASCO guidelines for your tumor type and stage. If additional staging is needed — PET-CT, CT-guided biopsy, molecular profiling by next-generation sequencing (NGS) — the oncologist coordinates this at the partner hospital before final assessment.

  3. 03

    Multi-disciplinary tumor board presentation

    Your case is presented at the partner hospital multi-disciplinary tumor board (MDT/MTB) per NCCN standard — the same format required by Joint Commission International (JCI). The tumor board includes the medical oncologist, radiation oncologist, relevant surgical oncologist (hepatobiliary, thoracic, colorectal, breast, urological as applicable), diagnostic radiologist, and pathologist. The board reaches a consensus recommendation. For complex or rare tumors, a second international tumor board opinion can be arranged. This is the standard of care for solid tumor management — individual physician assessment without MDT is not our practice.

  4. 04

    Written care plan + treatment pathway decision

    You receive a written care plan within 3–5 working days of your tumor board: confirmed staging and pathology interpretation, recommended treatment intent (curative-intent, neoadjuvant, adjuvant, palliative/disease-control — clearly stated), recommended systemic therapy regimen with drug names, doses, cycle schedule, and ESMO/NCCN evidence level, expected duration, monitoring schedule (imaging, lab markers), side-effect profile specific to your regimen, and palliative care and psycho-oncology support pathway. If the tumor board determines the most appropriate treatment is in your home country (for example, a highly specialised CAR-T programme or a clinical trial you have eligibility for at your local centre), we state this in writing rather than proceed with treatment that serves our business interest over your clinical interest.

  5. 05

    Treatment coordination and administration

    If you proceed with treatment in Istanbul: treatment is delivered at the partner JCI-aligned hospital by your named medical oncologist and nursing team. Pre-chemotherapy workup: baseline labs (CBC, CMP, LFTs, renal function, tumour markers), cardiology clearance (baseline ECHO for anthracycline regimens), pharmacy review. Chemotherapy administration takes place in a dedicated oncology day unit (IV access, antiemetic pre-medication, vital signs monitoring, nurse-to-patient ratio per national standards). Immunotherapy infusions include standard pre-medication and extended post-infusion observation for immune-related adverse events (irAEs) — your care team is familiar with irAE recognition and management (colitis, pneumonitis, endocrinopathy).

  6. 06

    Response assessment and ongoing coordination

    Response assessment per RECIST 1.1 criteria (CT/MRI at defined intervals). Tumour marker monitoring (CEA for colorectal, CA-125 for ovarian, PSA for prostate, CA 15-3 for breast). Structured management of treatment toxicity — chemotherapy dose modifications per published criteria (CTCAE grading), immunotherapy irAE protocols, supportive care (growth factors, anti-emetics, neuropathy management). At completion or disease progression, a formal re-presentation to the multi-disciplinary tumor board determines next-line options. Palliative care and psycho-oncology support are offered at every stage — these are not failure states but part of comprehensive cancer care.

Systemic therapy pathways

Chemotherapy vs Immunotherapy vs Targeted Therapy vs Hormone Therapy

The right systemic therapy depends on cancer type, molecular profile, prior treatment history, and patient performance status. Here is how the four main categories differ:

Aspect Chemotherapy Immunotherapy (checkpoint inhibitors) Targeted therapy (TKIs / mAbs) Hormone therapy
Mechanism Cytotoxic — kills rapidly dividing cells (cancer and some normal cells) Immune checkpoint release — anti-PD-1/PD-L1 (nivolumab, pembrolizumab, atezolizumab), CTLA-4 (ipilimumab) unblock T-cell anti-tumour response Molecular-matched — TKIs (erlotinib, osimertinib, imatinib, lapatinib), monoclonal antibodies (trastuzumab, cetuximab) against specific oncogenic driver Endocrine deprivation — aromatase inhibitors (anastrozole, letrozole), anti-androgens (enzalutamide, abiraterone) for hormone-sensitive tumors
Main indications Most solid tumor types; first-line and adjuvant in many cancers; hematological malignancies Solid tumors with PD-L1 expression or MSI-H/dMMR — melanoma, NSCLC, HNSCC, urothelial, RCC, gastric, CRC MSI-H; expanding broadly EGFR-mutant NSCLC, ALK-positive NSCLC, HER2+ breast, BCR-ABL+ CML, BRAF V600 melanoma, RET-altered tumors — requires molecular profiling ER+ HER2- breast cancer (adjuvant + metastatic), castration-sensitive and -resistant prostate cancer
Side-effect profile Myelosuppression (neutropenia, thrombocytopenia), nausea/vomiting, alopecia, mucositis, neuropathy (taxane, platinum), cardiotoxicity (anthracyclines) Immune-related adverse events (irAEs) — colitis (3–10%), pneumonitis (1–5%), endocrinopathies (thyroid, pituitary), hepatitis, dermatitis; potentially life-threatening (grade 3–4 in 15% combination) Regimen-specific: TKIs — rash, diarrhoea, hepatotoxicity, QT prolongation; anti-HER2 — cardiac monitoring required; VEGFR — hypertension, wound healing delay Vasomotor symptoms (hot flushes), bone density loss (osteoporosis), sexual dysfunction, fatigue; aromatase inhibitors: arthralgias
Requires biomarker testing No (broad activity), but HER2/ER/PR status informs regimen choice in breast PD-L1 IHC (TPS/CPS), MSI/MMR status, TMB — some indications require PD-L1 ≥50% (pembrolizumab 1L NSCLC) Yes — molecular profiling mandatory (NGS or specific PCR/FISH for each target) Yes — hormone receptor status (ER/PR IHC) + HER2 status mandatory
Typical administration IV infusion cycles (every 2–3 weeks, 3–6 months typical adjuvant), day unit, pre-medication required IV infusion every 2–4 or 6 weeks; extended post-infusion observation; irAE monitoring protocol Oral daily (most TKIs); some IV (cetuximab, trastuzumab every 1–3 weeks) Oral daily (anastrozole, letrozole, tamoxifen, enzalutamide) or monthly/quarterly IM injection (LHRH agonists)
Pricing

Personalised pricing

Every treatment plan is priced individually after your consultation. Request a written, all-inclusive quote — clear, itemised, and with no obligation.

Request a written quote
Package transparency

What's included in your oncology coordination

Included in coordination

  • Initial oncology consultation with board-certified medical oncologist (partner network)
  • Document review and staging workup gap assessment
  • Multi-disciplinary tumor board (MDT) case presentation
  • Written care plan: confirmed staging, treatment intent (curative/palliative clearly stated), regimen, ESMO/NCCN evidence level, monitoring schedule
  • Side-effect profile and patient information document for your specific regimen
  • Palliative care and psycho-oncology pathway information (included as standard, not presented as failure)
  • Coordination of PET-CT, CT staging, or NGS molecular profiling at partner hospital if required
  • Treatment administration at JCI-aligned partner hospital (day unit, IV access, nursing care)
  • Ongoing toxicity management and dose modification per CTCAE grading criteria
  • Response assessment coordination (RECIST 1.1, tumour markers)
  • Multilingual care coordinator — from first contact to response assessment
  • Complication insurance policy (Türkiye Ministry of Health certified, covers surgical complications including infection, retreatment, and emergency intervention up to package value)

Quoted separately

  • Chemotherapy drug cost (quoted separately — depends on regimen, number of cycles, body surface area)
  • Immunotherapy drug cost (pembrolizumab, nivolumab, atezolizumab, ipilimumab — high-cost agents quoted separately)
  • Targeted therapy drug cost (TKIs and monoclonal antibodies quoted separately)
  • Radiotherapy (radiation oncology is a separate discipline — coordinated through partner radiation oncology team if indicated by tumor board)
  • Surgical oncology procedures (tumour resection, lymph node dissection — separate from medical oncology)
  • Clinical trial participation (we assist with eligibility screening; clinical trial costs vary by protocol)
  • Hotel and accommodation (quoted separately based on treatment duration)
  • Flights to/from Istanbul
  • Travel insurance (recommended — covers flight cancellation, baggage, non-surgical medical emergencies abroad; we coordinate referral if needed)
Candidacy

Is oncology coordination at Eyeglow Health right for you?

You may benefit from coordination if

  • You have a confirmed cancer diagnosis and are seeking a second opinion on your pathology, staging, or proposed treatment plan from a different specialist team.
  • You have a solid tumor (breast, colorectal, lung, prostate, stomach, ovarian, bladder, head and neck, kidney) or hematological malignancy (lymphoma, leukemia — consultation and coordination) and are exploring treatment options.
  • Your molecular profiling result (NGS) shows a targetable driver mutation and you want assessment of approved targeted therapy options in Turkey.
  • Your tumor has been determined to be PD-L1-expressing or MSI-H/dMMR and you are exploring immunotherapy eligibility.
  • You are seeking treatment in Istanbul because wait times for treatment initiation are delaying your care at home — we can provide rapid staging confirmation and treatment commencement.
  • You are interested in coordination of palliative systemic therapy or supportive cancer care.

Coordination through Eyeglow Health may not be appropriate if

  • You are seeking CAR-T cell therapy, stem cell transplantation, or experimental early-phase clinical trials — these require highly specialised infrastructure (apheresis unit, haematology BMT programme, GCP-compliant trial site); we will refer you to appropriate centres rather than oversell our capabilities.
  • You expect a "cure" guarantee — we cannot and will not make cure claims. Oncology treatment outcomes depend on cancer type, stage, molecular biology, patient factors, and biology of the tumour. We present honest evidence-based survival and response statistics for your specific diagnosis.
  • You require proton beam therapy — this is not currently available in our partner network in Istanbul; we will direct you to appropriate European proton centres if indicated.
  • Your home-country oncology team has offered standard-of-care treatment that is available to you without significant delay — if your local care is appropriate and accessible, we will say so.

Disclaimer. Information on this page is consistent with ESMO Clinical Practice Guidelines, NCCN Guidelines (National Comprehensive Cancer Network), and ASCO Practice Guidelines. Statistics cited are sourced from peer-reviewed published trials and registry data. Oncology outcomes are highly individual — survival statistics represent population medians and do not predict individual outcomes. Treatment decisions require assessment by a board-certified medical oncologist with access to your full medical records.

Honest disclosure

What every oncology patient should understand

Oncology carries the highest YMYL stakes of any medical field. We communicate the following plainly — the same way our partner oncologist does in your first consultation:

Honest oncology outcome disclosure — treatment aims to control, not always to cure

For many cancer diagnoses, treatment intention is disease control, response, and quality of life extension — not cure. ESMO and NCCN distinguish curative-intent from palliative/disease-control intent treatment in all guideline statements. We state treatment intent explicitly in every care plan. Example: stage IV non-small cell lung cancer with EGFR mutation treated with osimertinib has a median progression-free survival of approximately 18 months (FLAURA trial) — this is a meaningful, evidence-based outcome, but it is not a cure. We will not describe it as one.

Chemotherapy toxicity — myelosuppression, nausea, neuropathy, cardiotoxicity

Chemotherapy causes clinically significant side effects in a majority of patients. Myelosuppression (neutropenia) occurs in 30–60% depending on regimen — febrile neutropenia risk is 5–20% in intensive regimens and requires prophylactic growth factor support (G-CSF) or dose modification. Anthracycline regimens (doxorubicin, epirubicin) carry a cumulative cardiotoxicity risk — baseline and serial ECHO monitoring is required; lifetime cumulative dose thresholds (e.g. doxorubicin <450 mg/m²) are strictly observed. Platinum-taxane combinations (NSCLC, ovarian, breast) carry peripheral neuropathy risk (30–50%); dose modification or dose delay is part of standard toxicity management per CTCAE grading criteria.

Immunotherapy — immune-related adverse events (irAEs) can be severe

Immune checkpoint inhibitors (anti-PD-1, PD-L1, CTLA-4) cause immune-related adverse events (irAEs) in 15–90% of patients depending on agent and combination. Grade 1–2 irAEs (manageable) occur in 60–70%; grade 3–4 (severe, potentially life-threatening) occur in 15–20% with combination ipilimumab + nivolumab. Key irAEs: immune colitis (diarrhoea, abdominal pain — requires early steroid intervention; severe cases require infliximab), pneumonitis (breathlessness, cough — can be life-threatening; immediate high-dose steroids + hold immunotherapy), endocrinopathy (thyroid dysfunction in 5–10%, hypophysitis in 1–5%), hepatitis, dermatitis (including Steven-Johnson syndrome, rare), nephritis. Our partner team has irAE recognition and management protocols in place.

Targeted therapy — molecular profiling required, resistance inevitable for most agents

Targeted therapies require documented presence of the molecular target (driver mutation or receptor overexpression) — prescribing off-target is not evidence-based. For most approved TKIs, acquired resistance develops (median 12–18 months for EGFR TKIs, 6–12 months for BRAF inhibitors in melanoma) and requires next-line therapy reassessment. Molecular profiling by NGS is required at diagnosis and often at progression to identify resistance mechanisms (e.g. T790M EGFR for osimertinib eligibility). Our partner oncologist ensures profiling is adequate before recommending targeted therapy — prescribing based on incomplete molecular data is not our practice.

Palliative care is part of good oncology, not a final resort

Per ASCO and ESMO consensus guidelines, early integration of palliative care alongside oncological treatment improves quality of life and in some studies (Temel 2010, NEJM) overall survival. We include palliative care and psycho-oncology information at every stage of the care plan — for the patient, and for family members as caregivers. Hospice referral is discussed openly when curative or life-prolonging treatment is no longer in the patient's interest — this conversation, done well, is an act of care, not abandonment.

FAQ

Frequently asked questions about medical oncology in Turkey

What is medical oncology and how is it different from surgical oncology?
Medical oncology is the medical specialty focused on diagnosis and non-surgical treatment of cancer — chemotherapy, immunotherapy, targeted therapy, and hormone therapy. The medical oncologist leads systemic treatment. Surgical oncology involves the surgical removal of tumors and is performed by a surgical oncologist (a specialist surgeon). Radiation oncology delivers radiotherapy (X-ray, proton beam). Most cancer patients require care from all three disciplines — which is why the multi-disciplinary tumor board (MDT/MTB), where all three specialties review the case together, is the standard of care per NCCN, ESMO, and JCI requirements. At Eyeglow Health, we coordinate all three components through our partner specialist network, with the tumor board as the central decision-making structure.

Why is a second oncology opinion valuable?
Large published studies (Blumenthal 2018, JCO; Payne 2019, Annals of Oncology) show that independent second opinion changes the recommended treatment plan in 10–30% of cases — through reclassification of stage, revision of pathology interpretation, identification of an unrecognised targetable mutation, or recognition that a less aggressive regimen is appropriate. Second opinions are standard practice in oncology at major cancer centres (MD Anderson, Memorial Sloan Kettering, Mayo Clinic) — they are not a criticism of your first oncologist; they are a form of clinical risk management. At Eyeglow Health, a second opinion includes full document review, tumor board presentation, and a written comparison of your current plan vs the tumor board recommendation.

What is a multi-disciplinary tumor board and why does it matter?
A multi-disciplinary tumor board (MDT or tumor board conference) is a formal meeting where a medical oncologist, radiation oncologist, relevant surgical oncologist, diagnostic radiologist, and pathologist review a patient's case together and reach a consensus treatment recommendation. NCCN requires tumor board review for all complex solid tumor cases. JCI accreditation standards require MDT infrastructure. Evidence consistently shows better outcomes (survival, treatment completion, complication rates) at centres with active tumor board programmes compared to individual physician decision-making. For brain tumors, pancreatic cancer, borderline resectable colorectal liver metastases, and locally advanced thoracic tumors, the MDT recommendation determines whether surgery, systemic therapy, or combined modality treatment is appropriate — a decision that is genuinely difficult without multi-specialist input. We do not proceed without tumor board review.

Am I eligible for immunotherapy?
Immunotherapy eligibility depends on your cancer type, tumour biomarker status, and prior treatment history. PD-L1 expression (tested by immunohistochemistry on your pathology sample): pembrolizumab is approved first-line for NSCLC with PD-L1 tumour proportion score (TPS) ≥50% (KEYNOTE-024), for any PD-L1 expression in combination with chemotherapy (KEYNOTE-189, KEYNOTE-407), and for multiple other tumor types at various PD-L1 thresholds. MSI-H/dMMR status (microsatellite instability high / mismatch repair deficient): pembrolizumab (KEYNOTE-158) is approved for any solid tumor MSI-H/dMMR regardless of tumor site — this is the first tumour-agnostic FDA approval. TMB-high (tumour mutational burden high) — also pembrolizumab agnostic approval. If your tumour has not been tested for PD-L1, MSI status, or TMB, our partner oncologist will arrange this testing before immunotherapy is recommended.

What are the honest side effects of chemotherapy?
Chemotherapy side effects vary significantly by regimen. Universal acknowledgement: nausea and vomiting (well-controlled with modern antiemetics — 5-HT3 antagonists, NK1 antagonists, dexamethasone; severe in <10% with optimal pre-medication). Alopecia: regimen-dependent — anthracyclines and taxanes cause complete hair loss in most patients; platinum, cyclophosphamide variable; anti-metabolites (5-FU, capecitabine) generally do not. Myelosuppression (neutropenia, anaemia, thrombocytopenia): most common serious toxicity — managed with dose reduction, schedule modification, G-CSF prophylaxis; hospital admission for febrile neutropenia is a real risk (5–20% depending on regimen intensity). Peripheral neuropathy (numbness, tingling, pain in hands and feet): platinum and taxane agents — cumulative, partially reversible; dose modification required at grade 2+. Fatigue: universal, varies in severity; often the most impactful quality-of-life effect. Cardiotoxicity: anthracyclines (doxorubicin, epirubicin) — monitored with serial ECHO, cumulative dose-limited. We provide regimen-specific patient information at the start of treatment.

Is palliative care available and what does it include?
Palliative care is available and is integrated into every treatment plan — not reserved for end-of-life. Per ASCO and ESMO guidelines, early palliative care integration alongside oncological treatment is evidence-based and improves quality of life, reduces treatment toxicity burden, and supports both patient and caregiver wellbeing. At our partner hospital, palliative care services include: symptom management (pain control, nausea management, dyspnoea management, ascites/pleural effusion drainage), nutritional support and dietitian consultation, psycho-oncology (psychological support for patient and family), spiritual care coordination, social work support for family burden, and advance care planning discussions. Hospice and end-of-life care coordination is offered openly and without hesitation when curative or disease-modifying treatment is no longer in the patient's best interest — at Eyeglow Health we will tell you when we have reached that point, rather than continuing active treatment that prolongs suffering without meaningful benefit.

What is molecular profiling (NGS) and when is it recommended?
Molecular profiling — most commonly by next-generation sequencing (NGS) of tumour tissue or cell-free tumour DNA (liquid biopsy) — identifies specific genomic alterations (driver mutations, amplifications, fusions, deletions) that may be targetable with approved drugs or predict response to immunotherapy. NGS is recommended (ESMO Precision Medicine Working Group, NCCN Biomarker guidelines): for all advanced non-small cell lung cancer (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET exon 14, RET, NTRK — 8+ actionable targets in NSCLC); for colorectal cancer (KRAS/NRAS/BRAF, MSI, HER2); for breast cancer (PIK3CA for alpelisib, BRCA for olaparib/talazoparib, ESR1 for fulvestrant/elacestrant); for prostate cancer (BRCA1/2/homologous recombination repair for olaparib/rucaparib); for any cancer for MSI/TMB (pembrolizumab agnostic indications). If your tumor has not been profiled, our partner oncologist will recommend appropriate testing before finalising your treatment plan.

Can I receive cancer treatment if I am already being treated abroad?
Yes — many patients transition part of their care to Istanbul, particularly for phases of treatment that are logistically feasible to deliver in a shorter stay (a defined number of chemotherapy cycles, second-opinion assessment with return home for local treatment continuation, molecular profiling). We coordinate with your home-country oncology team — our written care plan is designed to be shared with your local oncologist. We do not create care fragmentation; we make the Istanbul component explicit and ensure continuity of records. For patients relocating entirely to Istanbul for an extended treatment period, we provide full coordination including accommodation and ongoing care.

What is the difference between curative intent and palliative intent treatment?
Treatment intent is one of the most important concepts in oncology and one of the most honestly communicated in good clinical practice. Curative-intent treatment aims for disease eradication — typically applied in early-stage localised cancers where surgery, radiotherapy, and/or chemotherapy can eliminate all detectable disease (e.g. stage I–II colon cancer after resection, stage II–III breast cancer with adjuvant chemotherapy, early Hodgkin lymphoma with ABVD chemotherapy). Palliative-intent (also called non-curative or disease-control intent) treatment aims to control disease growth, relieve symptoms, and extend life expectancy — typically applied in stage IV metastatic disease where cure is not achievable with current treatments. A patient with stage IV ER+ breast cancer on aromatase inhibitor is receiving palliative-intent treatment with median survival of 3–5+ years in favourable biology; this is meaningful life extension and not failure. We state treatment intent clearly in every care plan rather than leaving it ambiguous.

What experimental or off-label treatments are available?
We offer access to approved treatments per ESMO, NCCN, and ASCO guidelines — this is our standard. Off-label use of approved agents is possible in specific situations where evidence supports it (published phase 2 trial data, NCCN category 2B evidence, institutional tumour board consensus) — but off-label use is discussed explicitly with the patient as such, with the evidence base clearly stated. We do not offer unproven treatments (unregulated "immunotherapy" compounds, unapproved stem cell infusions, extreme high-dose supplements as cancer treatment, non-evidence-based metabolic protocols) as cancer treatment at our partner hospitals. If you have been offered treatment elsewhere that lacks regulatory approval or guideline support, our partner oncologist can give you an honest independent assessment of the evidence.

Why does Eyeglow Health coordinate oncology if its primary specialty is ophthalmology?
Eyeglow Health's primary clinical specialty is ophthalmology — eye surgery and ophthalmic treatments. We coordinate medical oncology, neurosurgery, DBS, and other complex specialties through our accredited partner specialist network because patients who come to Turkey for medical tourism often have complex needs spanning multiple disciplines. Rather than referring patients to an unknown provider, we extend our coordination infrastructure — care coordinator, complication insurance, logistics, written care plan — to partner with board-certified specialists in these fields at JCI-aligned hospitals in Istanbul. The operating oncologist and clinical team are our vetted specialist partners; the care infrastructure and patient responsibility remain Eyeglow's. We do not undertake cases where our partner team determines a different clinical pathway is more appropriate for the patient.
Request second opinion